Office Action Predictor
Application No. 18/001,605

COMPOSITIONS FOR TREATING KERATIN FIBERS

Final Rejection §103
Filed
Dec 13, 2022
Examiner
PACKARD, BENJAMIN J
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Revlon Consumer Products Corporation
OA Round
2 (Final)
66%
Grant Probability
Favorable
3-4
OA Rounds
2y 11m
To Grant
74%
With Interview

Examiner Intelligence

66%
Career Allow Rate
867 granted / 1314 resolved
Without
With
+8.0%
Interview Lift
avg trend
2y 11m
Avg Prosecution
45 pending
1359
Total Applications
career history

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
44.2%
+4.2% vs TC avg
§102
18.5%
-21.5% vs TC avg
§112
14.5%
-25.5% vs TC avg
Black line = Tech Center average estimate • Based on career data

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments, filed XXXXXXX, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 1, 2-4, 10-12, and 15-16 are rejected under 35 U.S.C. 103 as being unpatentable over Maruyama et al (US 2006/0088490) in view of Herrlein et al (EP 328163). Maruyama et al teaches a method of treating hair comprising applying an inside repair agent, methylhydrogen polysiloxane, polymers of Formula 1, an acid, a coating agent comprising amino functional silicone (claim 1). The inside repair agent can be a polypeptide, including hydrolyzed vegetable protein propylene glycol propylsilanetriol (¶ 20). The amino functional silicones have a main chain of silicone and a side chain of amino group where the amino functional silicone is used for hair inside repair agent to produce easiness in combing, soft feel, and sheen, as well as protection from hair dryer (¶ 23). The protein derivative may be present from 0.01 to 1 mass%, and the amino functional silicone can be present from 0.1 to 3 mass% (¶ 37). The composition can be used to treat frizzy hair (¶ 30) and provide protection from heat damage (¶ 53). Maruyama et al does not teach polysilicone-29, -33, or -35 as the preferred film forming amino-silicone polymers. Herrlein et al teaches polysilicone-29 was a known amino functional silicone used in hair products (¶ 150). It would have been obvious to one of ordinary skill in the art to substitute known amino functional silicones, such as taught by Herrlein et al, into the composition of Maruyama et al, given both are film forming hair components. It would then have been obvious to vary the amount of each component based on the teaching of Maruyama et al in order to produce a hair composition having the desired effects, i.e. reducing hair frizz and protecting from heat damage. Examiner notes that Applicants presented arguments with regards to the combination of both a amino functional silicones and protein silicone derivative, but as noted in the rejection above, Maruyama et al teaches the inclusion of both components. Thus, the showing of individual components compared to the combination do not overcome the new rejection. To overcome this rejection, a showing would have to demonstrate unexpected results with regards to the use of polysilicone-29, 33, and 35 over other amino functional silicones. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BENJAMIN J PACKARD whose telephone number is (571)270-3440. The examiner can normally be reached Mon 2-6pm and Tues-Fri (9am-6pm + mid-day flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sandy Kaup can be reached at (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BENJAMIN J PACKARD/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Dec 13, 2022
Application Filed
Sep 06, 2025
Non-Final Rejection — §103
Oct 27, 2025
Response Filed
Jan 09, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology. Study what changed to get past this examiner.

Patent 12589111
PT(IV) CHEMOTHERAPEUTIC PRODRUG AND CONTROLLED RELEASE THEREOF FOR TREATMENT OF TUMORS
2y 5m to grant Granted Mar 31, 2026
Patent 12582745
ADHESIVE COMPOSITION FOR HARD TISSUE REPAIR
2y 5m to grant Granted Mar 24, 2026
Patent 12583865
Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration
2y 5m to grant Granted Mar 24, 2026
Patent 12582586
Oral Care Compositions
2y 5m to grant Granted Mar 24, 2026
Patent 12576105
COMPOSITIONS FOR TREATING JOINT OR CONNECTIVE TISSUE DISEASE COMPRISING DEXTRAN OR POLOXAMER
2y 5m to grant Granted Mar 17, 2026

AI Strategy Recommendation

Click below to generate an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
66%
Grant Probability
74%
With Interview (+8.0%)
2y 11m
Median Time to Grant
Moderate
PTA Risk
Based on 1314 resolved cases by this examiner